Martin J Kendall
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Martin J Kendall has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
S. L. Nuttall
Department of Clinical Pharmacology, Division of Medical Sciences and Wolfson Applied Technology Laboratory, Queen Elizabeth Hospital, Birmingham, UK
5 shared publications- S. L. Nuttall
Division of Medical Sciences, University of Birmingham, Birmingham and Medicines Control Agency, London, UK
2 shared publications - V. Toescu
Division of Medical Sciences, University of Birmingham, UK
2 shared publications Dinesh K Mehta
Royal Pharmaceutical Society of Great Britain, London, UK
1 shared publicationG. H. Thorpe
1 shared publicationJ Misson
Department of Medicines Management, Keele University, UK
1 shared publication
Latest Publications
- 1 January 2006
- Published by Elsevier in The Lancet
- Vol. 367 (9507) , 281-283
Sick children deserve a better deal
- 1 January 2006
- Published by Elsevier in The Lancet
- Vol. 367 (9507) , 281-283
Sick children deserve a better deal
- 11 August 2003
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 28 (4) , 251-257
Does paracetamol cause asthma?
- 11 August 2003
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 28 (4) , 251-257
Does paracetamol cause asthma?
- 11 August 2003
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 28 (4) , 289-294
The impact of therapeutic doses of paracetamol on serum total antioxidant capacity
Introduction: A link between regular paracetamol intake and asthma in adults has recently been postulated. Detoxification of paracetamol may deplete stores of glutathione, which is one of the major ...
- 11 August 2003
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 28 (4) , 289-294
The impact of therapeutic doses of paracetamol on serum total antioxidant capacity
Introduction: A link between regular paracetamol intake and asthma in adults has recently been postulated. Detoxification of paracetamol may deplete stores of glutathione, which is one of the major ...
- 28 February 2003
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 28 (1) , 1-4
Coronary artery disease - more disease, more patients, better treatment
Click on the article title to read more.
- 28 February 2003
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 28 (1) , 1-4
Coronary artery disease - more disease, more patients, better treatment
Click on the article title to read more.
- Open Access
- 1 February 2003
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 17 (s1) , 1-4
Review article: esomeprazole − the first proton pump inhibitor to be developed as an isomer
Summary: Omeprazole is a racemate, from which the R‐ and S‐isomers can be isolated. At the cellular level, both of these isomers convert to the same inhibitor of the H+,K+‐ATPase and produce the same reduction in gastric acid secretion. However, the S‐isomer, esomeprazole, is metabolized more slowly and reproducibly than the R‐isomer and omeprazole, and therefore produces higher plasma concentrations for longer and, as a result, inhibits gastric acid production more effectively and for longer. Thus, esomeprazole has the pharmacological properties of a more effective form of treatment for disorders related to gastric acid secretion. Clinical studies have confirmed the anticipated increased efficacy, but have shown no evidence of impaired tolerability or increased toxicity when compared with omeprazole.
- 1 February 2003
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 17 (s1) , 1-4
Open AccessReview article: esomeprazole − the first proton pump inhibitor to be developed as an isomer
Summary: Omeprazole is a racemate, from which the R‐ and S‐isomers can be isolated. At the cellular level, both of these isomers convert to the same inhibitor of the H+,K+‐ATPase and produce the same reduction in gastric acid secretion. However, the S‐isomer, esomeprazole, is metabolized more slowly and reproducibly than the R‐isomer and omeprazole, and therefore produces higher plasma concentrations for longer and, as a result, inhibits gastric acid production more effectively and for longer. Thus, esomeprazole has the pharmacological properties of a more effective form of treatment for disorders related to gastric acid secretion. Clinical studies have confirmed the anticipated increased efficacy, but have shown no evidence of impaired tolerability or increased toxicity when compared with omeprazole.
- 1 August 2002
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 27 (4) , 233-242
The cardioprotective role of beta-blockers in patients with diabetes mellitus
This paper reviews the role of beta-blockers in the prevention of cardiovascular morbidity and mortality in patients with diabetes mellitus. There is good evidence from randomized controlled trials that beta-blockers, in particular the lipophilic agents, substantially reduce cardiovascular mortality and morbidity. However, hitherto beta-blockers have been underused in diabetic patients, perhaps because of perceived risks of beta-blocker therapy. Reappraisal of the evidence suggests that the traditional reluctance to use beta-blockers in this group is based on fears of adverse effects that are largely unfounded
- 1 August 2002
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 27 (4) , 233-242
The cardioprotective role of beta-blockers in patients with diabetes mellitus
This paper reviews the role of beta-blockers in the prevention of cardiovascular morbidity and mortality in patients with diabetes mellitus. There is good evidence from randomized controlled trials that beta-blockers, in particular the lipophilic agents, substantially reduce cardiovascular mortality and morbidity. However, hitherto beta-blockers have been underused in diabetic patients, perhaps because of perceived risks of beta-blocker therapy. Reappraisal of the evidence suggests that the traditional reluctance to use beta-blockers in this group is based on fears of adverse effects that are largely unfounded
- Open Access
- 1 February 2002
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 27 (1) , 1-4
The heart protection study: statins for all those at risk?
On 13 November 2001, Professor Rory Collins, Co-director of the Oxford University's Clinical Trial Service Unit, presented the results of the Heart Protection Study (HPS) at the American Heart Association. This was noted in the British Medical Journal (BMJ) on 17 November (1) and the relevant information was made available on a website (http:/www.hpsinfo.org). A full paper will presumably be published in the not too distant future. This paper and the data already made available will have a marked impact on the assessment and management of patients at risk of dying from cardiovascular disease. The results may shift the emphasis in cardiovascular medicine away from expensive invasive procedures, such as
- 1 February 2002
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 27 (1) , 1-4
Open AccessThe heart protection study: statins for all those at risk?
On 13 November 2001, Professor Rory Collins, Co-director of the Oxford University's Clinical Trial Service Unit, presented the results of the Heart Protection Study (HPS) at the American Heart Association. This was noted in the British Medical Journal (BMJ) on 17 November (1) and the relevant information was made available on a website (http:/www.hpsinfo.org). A full paper will presumably be published in the not too distant future. This paper and the data already made available will have a marked impact on the assessment and management of patients at risk of dying from cardiovascular disease. The results may shift the emphasis in cardiovascular medicine away from expensive invasive procedures, such as
- 1 December 2001
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 26 (6) , 391-395
Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?
- 1 December 2001
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 26 (6) , 391-395
Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?
- Open Access
- 20 August 2001
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 26 (4) , 231-233
Prostate cancer and antioxidants
Click on the article title to read more.
- 20 August 2001
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 26 (4) , 231-233
Open AccessProstate cancer and antioxidants
Click on the article title to read more.